⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17752519 | 1.00 | — | — | |
| SCHEMBL15140933 | 1.00 | — | — | |
| SCHEMBL2121263 | 1.00 | — | — | |
| SCHEMBL12680318 | 0.99 | PSMB8 (0.30) | — | |
| SCHEMBL12972215 | 0.86 | ADORA3 (0.31) | — | |
| SCHEMBL13907086 | 0.86 | PSMB8 (0.30) | — | |
| SCHEMBL31529657 | 0.85 | — | — | |
| SCHEMBL15059308 | 0.85 | — | — | |
| SCHEMBL264659 | 0.85 | CYP2C19 (0.32) | — | |
| SCHEMBL17776321 | 0.85 | PSMB8 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626462-A1 | GLUCOCEREBROSIDASE (GBA) POLYMER CONJUGATE, PREPARATION METHOD AND USE FOR NANOTECHNOLOGICAL BASED ENZYME REPLACEMENT THERAPY | Fundació Hospital Universitari Vall Hebron - Institut de Recerca (ES) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024115612-A1 | GLUCOCEREBROSIDASE (GBA) POLYMER CONJUGATE, PREPARATION METHOD AND USE FOR NANOTECHNOLOGICAL BASED ENZYME REPLACEMENT THERAPY | FUNDACIÓ HOSPITAL UNIVERSITARI VALL HEBRON - INSTITUT DE RECERCA (VHIR) (ES) | 2024-06-06 | — | — | WO | disclosed |
| US-9586916-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2806899-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN-LA ROCHE INC. (US) | 2015-02-05 | — | — | US | disclosed |